Advertisement

Topics

ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions

11:45 EST 20 Dec 2018 | Investing News Network

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration has issued a Complete Response Letter for the drug substance Prior Approval Supplement submission … Continued

The post ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions appeared first on Investing News Network.

Original Article: ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions

NEXT ARTICLE

More From BioPortfolio on "ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...